International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Standard
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. / Cavo, Michele; Rajkumar, S Vincent; Palumbo, Antonio; Moreau, Philippe; Orlowski, Robert; Bladé, Joan; Sezer, Orhan; Ludwig, Heinz; Dimopoulos, Meletios A; Attal, Michel; Sonneveld, Pieter; Boccadoro, Mario; Anderson, Kenneth C; Richardson, Paul G; Bensinger, William; Johnsen, Hans E; Kröger, Nicolaus; Gahrton, Gösta; Bergsagel, P Leif; Vesole, David H; Einsele, Hermann; Jagannath, Sundar; Niesvizky, Ruben; Durie, Brian G M; Jesus, San Miguel; Lonial, Sagar; Group, International Myeloma Working.
in: BLOOD, Jahrgang 117, Nr. 23, 23, 2011, S. 6063-6073.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
AU - Cavo, Michele
AU - Rajkumar, S Vincent
AU - Palumbo, Antonio
AU - Moreau, Philippe
AU - Orlowski, Robert
AU - Bladé, Joan
AU - Sezer, Orhan
AU - Ludwig, Heinz
AU - Dimopoulos, Meletios A
AU - Attal, Michel
AU - Sonneveld, Pieter
AU - Boccadoro, Mario
AU - Anderson, Kenneth C
AU - Richardson, Paul G
AU - Bensinger, William
AU - Johnsen, Hans E
AU - Kröger, Nicolaus
AU - Gahrton, Gösta
AU - Bergsagel, P Leif
AU - Vesole, David H
AU - Einsele, Hermann
AU - Jagannath, Sundar
AU - Niesvizky, Ruben
AU - Durie, Brian G M
AU - Jesus, San Miguel
AU - Lonial, Sagar
AU - Group, International Myeloma Working
PY - 2011
Y1 - 2011
N2 - The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.
AB - The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.
KW - Age Factors
KW - Survival Rate
KW - Disease-Free Survival
KW - Transplantation, Autologous
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Stem Cell Transplantation
KW - Multiple Myeloma/mortality/therapy
KW - Age Factors
KW - Survival Rate
KW - Disease-Free Survival
KW - Transplantation, Autologous
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Stem Cell Transplantation
KW - Multiple Myeloma/mortality/therapy
M3 - SCORING: Journal article
VL - 117
SP - 6063
EP - 6073
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 23
M1 - 23
ER -
